Loading the section
Prices delayed by 15 minutes
Next earnings report: 03 November 2026, before market open · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Teva Pharmaceutical Industries Limited trades on NYSE under the ticker TEVA. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks TEVA has traded between 18.83 $ and 40.79 $. As of 09 October 2026 the price stood 92.99 % of the way from the 52-week low to the high.
Over one year TEVA shares rose 95.57 %; over six months they rose 26.78 %. Volatility over 90 days is 35.93 %. Dividends are not included: this is price change only, as of 09 October 2026.
TEVA trades at a price-to-earnings ratio of 31.8, above the sector median of 24.8. Price to sales is 2.9, below the sector median of 3.9. Price to book is 6.0, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 08 October 2026 | 38.84 | 39.64 | 38.25 | 39.25 | 6M |
| 07 October 2026 | 38.93 | 39.39 | 38.65 | 39.18 | 3M |
| 06 October 2026 | 39.65 | 39.93 | 38.85 | 39.13 | 6M |
| 05 October 2026 | 39.44 | 40.03 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Teva Pharmaceutical Industries Limited (TEVA) is a public company in the healthcare sector. Its common stock trade on NYSE.
Over the trailing twelve months as reported to 2025-12-31, revenue was 17.3bn $, net income was 1.4bn $. Incorporated in IL.
This summary is compiled automatically from SEC filings and exchange data.
Address:TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST., TEL AVIV
Teva Pharmaceutical Industries Limited reported revenue of 17.3B $ and net income of 1.6B $ over the last four quarters. Net margin is 9.02 %. Revenue changed by +4.41 % year over year. Earnings per share are 1.34 $. Market capitalisation is 49.8B $.
TEVA has a return on equity of 19.02 %, above the sector median of −41.68 %. Return on assets is 3.91 %, above the sector median of −32.11 %. Operating margin is 13.20 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 39.27 |
| 39.66 |
| 4M |
| 02 October 2026 | 39.31 | 39.81 | 39.05 | 39.53 | 5M |
| 01 October 2026 | 39.50 | 39.58 | 38.52 | 39.31 | 6M |
| 30 September 2026 | 40.20 | 40.28 | 39.22 | 39.60 | 6M |
| 29 September 2026 | 38.90 | 40.24 | 38.67 | 39.81 | 7M |
| 28 September 2026 | 38.36 | 39.11 | 38.30 | 38.88 | 4M |
| 25 September 2026 | 40.10 | 40.25 | 38.93 | 39.19 | 4M |
| 24 September 2026 | 38.74 | 40.31 | 38.63 | 40.22 | 8M |
| 23 September 2026 | 39.68 | 40.09 | 38.92 | 39.01 | 6M |
| 22 September 2026 | 39.45 | 40.14 | 39.05 | 39.52 | 5M |
| 21 September 2026 | 39.09 | 40.79 | 38.36 | 40.06 | 6M |
| 18 September 2026 | 38.90 | 39.38 | 38.66 | 38.98 | 5M |
| 17 September 2026 | 38.96 | 39.70 | 38.71 | 39.19 | 6M |
| 16 September 2026 | 39.02 | 39.52 | 38.32 | 38.53 | 5M |
| 15 September 2026 | 38.71 | 39.49 | 38.11 | 39.25 | 7M |
| 14 September 2026 | 37.66 | 39.22 | 37.00 | 38.72 | 4M |
| 11 September 2026 | 36.46 | 37.11 | 36.06 | 37.09 | 3M |